Beyond HbA1c: Artificial Intelligence and Gut Microbiome Metabolites for Predicting Diabetic Complications

Ghanbari, Elaheh

Volume 18, Issue 3 (8-2026) IJDO 2026, 18(3): 154-155 | Back to browse issues page

Mendeley

Zotero

RefWorks

Ghanbari E. Beyond HbA1c: Artificial Intelligence and Gut Microbiome Metabolites for Predicting Diabetic Complications. IJDO 2026; 18 (3) :154-155
URL: http://ijdo.ssu.ac.ir/article-1-1056-en.html

Beyond HbA1c: Artificial Intelligence and Gut Microbiome Metabolites for Predicting Diabetic Complications

Elaheh Ghanbari ^*

Student Research Committee, Department of Food Hygiene and Quality Control, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract: (32 Views)

Dear Editor,
I am writing to draw attention to the remarkable advances in integrating artificial intelligence (AI) and gut microbiome metabolomics for predicting diabetic complications. Despite achieving recommended HbA1c targets, many patients continue to develop diabetic microvascular complications (1).

Type of Study: Research | Subject: Special
Received: 2026/08/22 | Accepted: 2026/08/19 | Published: 2026/08/19

References

1. B Butler AE, English E, Kilpatrick ES, Östlundh L, Chemaitelly HS, Abu-Raddad LJ, et al. Diagnosing type 2 diabetes using Hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. Acta Diabetologica. 2021 Mar;58(3):279-300. [DOI:10.1007/s00592-020-01606-5]

2. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S128-s45. https://pmc.ncbi.nlm.nih.gov/articles/PMC11635034/ [DOI:10.2337/dc25-S006]

3. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. Journal of general internal medicine. 2014;29(2):388-94. [DOI:10.1007/s11606-013-2595-x]

4. Szrejder M, Piwkowska A. Gut Microbiome-Derived Short-Chain Fatty Acids in Glomerular Protection and Modulation of Chronic Kidney Disease Progression. Nutrients. 2025;17(17):2904. [DOI:10.3390/nu17172904]

5. Zhou Z, Zheng Z, Xiong X, Chen X, Peng J, Yao H, et al. Gut microbiota composition and fecal metabolic profiling in patients with diabetic retinopathy. Frontiers in Cell and Developmental Biology. 2021;9:732204. [DOI:10.3389/fcell.2021.732204]

6. Xu W, Xue W, Zhou Z, Wang J, Qi H, Sun S, et al. Formate might be a novel potential serum metabolic biomarker for type 2 diabetic peripheral neuropathy. Diabetes, Metabolic Syndrome and Obesity. 2023:3147-60. [DOI:10.2147/DMSO.S428933]

7. He F, Ng Yin Ling C, Nusinovici S, Cheng CY, Wong TY, Li J, et al. Development and external validation of machine learning models for diabetic microvascular complications: cross-sectional study with metabolites. Journal of Medical Internet Research. 2024;26:e41065. [DOI:10.2196/41065]

8. Xie X, Wu C, Huang Z, Zhou Y, Huang J, Dao F, et al. Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics. Briefings in bioinformatics. 2026;27(1):bbag083. [DOI:10.1093/bib/bbag083]

9. Carletti M, Pandit J, Gadaleta M, Chiang D, Delgado F, Quartuccio K, et al. Multimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes. Nature Medicine.2025;31(9):3121-7 [DOI:10.1038/s41591-025-03849-7]